Familial homozygous hypercholesterolaemia
The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.
Treatment with evolocumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with familial homozygous hypercholesterolaemia.
Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing evolocumab.
Patients must be treated by or in consultation with a consultant physician. The date of the consultation must be no more than 6 months before the application for a PBS authority.
Make all initial applications for authority approval to prescribe evolocumab for the treatment of familial homozygous hypercholesterolaemia in writing and:
- upload through Health Professional Online Services, or
- post to the PBS Complex Drugs Programs address
All initial applications must include a completed:
- authority prescription form, and
- Familial homozygous hypercholesterolaemia Initial PBS authority application (PB186)
A qualifying low density lipoprotein (LDL) cholesterol level must be provided at the time of application and be no more than 2 months old.
To make an application for continuing treatment, call the PBS Complex Drugs Programs enquiry line.
For more information call the PBS Complex Drugs Programs enquiry line.